Core Viewpoint - Roche has entered into an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and commercialize petrelintide, an amylin analog, as a standalone therapy and in combination with Roche's CT-388 [1][6]. Group 1: Collaboration Details - The collaboration will involve co-commercialization of petrelintide in the U.S. and Europe, while Roche will have exclusive rights in the rest of the world [6]. - Zealand Pharma will receive upfront cash payments totaling USD 1.65 billion, with potential total consideration of up to USD 5.3 billion based on development and sales milestones [7]. Group 2: Product Information - Petrelintide is currently in phase 2 clinical development and is designed for once-weekly subcutaneous administration, showing potential as a best-in-class amylin monotherapy [3][10]. - The combination of petrelintide with Roche's CT-388 aims to enhance efficacy and tolerability in treating cardiovascular, renal, and metabolic diseases [4][8]. Group 3: Market Context - Obesity is a significant global health challenge, expected to affect over 4 billion people by 2035, with over 200 related comorbidities [12][8]. - Advances in incretin science have opened new avenues for obesity treatment, highlighting the need for effective therapies [2].
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity